Lucid Diagnostics appoints John R. Palumbo, healthcare veteran, to board effective Sept 22, 2025

Lucid Diagnostics Inc.

John R. Palumbo appointed as Class B director, effective September 22, 2025, designated by convertible note holders.
Palumbo brings 40 years of healthcare leadership, including roles at AmerisourceBergen, Allscripts, and ValueHealth.
He will receive cash fees and equity awards per non-employee director compensation policy.
He currently serves on boards of PM Pediatrics, ivWatch, Qless, and chairs Brado advisory board.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.